Understanding the expression and activity profile of these enzymes (HAT and HDAC) in different COPD phenotypes may further enlarge our knowledge about COPD pathophysiology and may accelerate the development of specific targeted inhibitors, consequently leading to an improved direction and perspective of personalized therapy according to the patient COPD phenotype classification. The gene discussed is TMPRSS11D; the disease is chronic obstructive pulmonary disease.